DK0732935T3 - Lyofiliserede stamcellefaktorformuleringer - Google Patents

Lyofiliserede stamcellefaktorformuleringer

Info

Publication number: DK0732935T3
Authority: DK; Denmark
Prior art keywords: stem cell; cell factor; lyophilized; factor formulations; lyophilized stem
Prior art date: 1993-12-22

Application number

DK95906058T

Other languages

English (en)

Inventor

Susan I Hershenson

Original Assignee

Amgen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-12-22

Filing date

1994-12-21

Publication date

1999-08-02

1994-12-21 Application filed by Amgen Inc filed Critical Amgen Inc

1999-08-02 Application granted granted Critical

1999-08-02 Publication of DK0732935T3 publication Critical patent/DK0732935T3/da

Links

238000009472 formulation Methods 0.000 title abstract 4
239000000203 mixture Substances 0.000 title abstract 4
210000000130 stem cell Anatomy 0.000 title abstract 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 abstract 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 abstract 1
229930195725 Mannitol Natural products 0.000 abstract 1
229930006000 Sucrose Natural products 0.000 abstract 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract 1
235000013922 glutamic acid Nutrition 0.000 abstract 1
239000004220 glutamic acid Substances 0.000 abstract 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 1
239000000594 mannitol Substances 0.000 abstract 1
235000010355 mannitol Nutrition 0.000 abstract 1
239000005720 sucrose Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Zoology (AREA)
Pharmacology & Pharmacy (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

DK95906058T 1993-12-22 1994-12-21 Lyofiliserede stamcellefaktorformuleringer DK0732935T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/172,507 US6288030B1 (en)	1993-12-22	1993-12-22	Stem cell factor formulations and methods
PCT/US1994/014739 WO1995017206A1 (en)	1993-12-22	1994-12-21	Lyophilized stem cell factor formulations

Publications (1)

Publication Number	Publication Date
DK0732935T3 true DK0732935T3 (da)	1999-08-02

Family

ID=22627993

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK95906058T DK0732935T3 (da)	1993-12-22	1994-12-21	Lyofiliserede stamcellefaktorformuleringer

Country Status (13)

Country	Link
US (4)	US6288030B1 (da)
EP (1)	EP0732935B1 (da)
CN (1)	CN1105575C (da)
AT (1)	ATE173402T1 (da)
AU (1)	AU696860B2 (da)
CA (1)	CA2182970C (da)
DE (1)	DE69414723T2 (da)
DK (1)	DK0732935T3 (da)
ES (1)	ES2123951T3 (da)
IL (1)	IL112088A (da)
NZ (1)	NZ278252A (da)
WO (1)	WO1995017206A1 (da)
ZA (1)	ZA9410189B (da)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6267958B1 (en)	1995-07-27	2001-07-31	Genentech, Inc.	Protein formulation
GB9515839D0 (en) *	1995-08-02	1995-10-04	Q One Biotech Ltd	Feline stem cell factor
TW518219B (en) *	1996-04-26	2003-01-21	Chugai Pharmaceutical Co Ltd	Erythropoietin solution preparation
US6017876A (en)	1997-08-15	2000-01-25	Amgen Inc.	Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
US6541033B1 (en)	1998-06-30	2003-04-01	Amgen Inc.	Thermosensitive biodegradable hydrogels for sustained delivery of leptin
US6420339B1 (en)	1998-10-14	2002-07-16	Amgen Inc.	Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US6245740B1 (en)	1998-12-23	2001-06-12	Amgen Inc.	Polyol:oil suspensions for the sustained release of proteins
US6500418B1 (en) *	1999-02-12	2002-12-31	The Washington University	Stimulating neutrophil function to treat inflammatory bowel disease
US8106098B2 (en)	1999-08-09	2012-01-31	The General Hospital Corporation	Protein conjugates with a water-soluble biocompatible, biodegradable polymer
US6472208B1 (en) *	1999-12-13	2002-10-29	Héma-Québec	Method of producing human IFN-α using sendai virus-infected hematopoietic stem cells
DK1349918T3 (da)	2000-12-06	2014-11-10	Anthrogenesis Corp	Fremgangsmåde til indsamling af stamceller fra moderkagen
US20080152629A1 (en) *	2000-12-06	2008-06-26	James Edinger	Placental stem cell populations
US7311905B2 (en) *	2002-02-13	2007-12-25	Anthrogenesis Corporation	Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
IL157350A0 (en)	2001-02-14	2004-02-19	Anthrogenesis Corp	Post-partum mammalian placenta, its use and placental stem cells therefrom
US20030191056A1 (en)	2002-04-04	2003-10-09	Kenneth Walker	Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
JP3963786B2 (ja) *	2002-06-11	2007-08-22	富士通株式会社	情報処理装置
JP2006509770A (ja) *	2002-11-26	2006-03-23	アンソロジェネシスコーポレーション	細胞治療学、細胞治療単位、およびそれらを利用した治療法
JP2006517975A (ja) *	2003-02-13	2006-08-03	アンスロジェネシスコーポレーション	疾患、障害または症状を患っている個体を治療するための臍帯血の使用
GB0321337D0 (en) *	2003-09-11	2003-10-15	Massone Mobile Advertising Sys	Method and system for distributing advertisements
EP1694328A4 (en) *	2003-12-02	2010-02-17	Celgene Corp	METHOD AND COMPOSITIONS FOR THE TREATMENT AND SUPPLY OF HEMOGLOBINOPATHY AND ANEMIA
EP2286791B1 (en)	2003-12-30	2014-03-26	Durect Corporation	Polymeric implants, preferably containing a mixture of PEG and PLG, for controlled release of active agents
ES2776657T3 (es)	2005-06-14	2020-07-31	Amgen Inc	Formulaciones de proteínas autotamponantes
WO2007016562A2 (en) *	2005-07-29	2007-02-08	Amgen Inc.	Formulations that inhibit protein aggregation
AU2006304277B2 (en)	2005-10-13	2012-07-05	Celularity Inc.	Immunomodulation using placental stem cells
US8455250B2 (en)	2005-12-29	2013-06-04	Anthrogenesis Corporation	Co-culture of placental stem cells and stem cells from a second source
ES2671355T3 (es)	2005-12-29	2018-06-06	Anthrogenesis Corporation	Poblaciones de células madre placentarias
AR059066A1 (es)	2006-01-27	2008-03-12	Amgen Inc	Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
EP1854478A1 (en) *	2006-05-12	2007-11-14	Cytos Biotechnology AG	Nicotine-carrier vaccine formulation
ZA200902233B (en)	2006-10-23	2010-07-28	Anthrogenesis Corp	Methods and compositions for treatment of bone defects with placental cell populations
SI2120977T1 (sl) *	2007-02-12	2014-01-31	Anthrogenesis Coroporation	Zdravljenje vnetnih bolezni z uporabo placentarnih matičnih celic
US20100172830A1 (en) *	2007-03-29	2010-07-08	Cellx Inc.	Extraembryonic Tissue cells and method of use thereof
TWM322542U (en) *	2007-05-23	2007-11-21	Universal Scient Ind Co Ltd	Testing machine
US9200253B1 (en)	2007-08-06	2015-12-01	Anthrogenesis Corporation	Method of producing erythrocytes
KR20220122774A (ko) *	2007-09-26	2022-09-02	셀룰래리티 인코포레이티드	인간 태반 관류액으로부터의 혈관형성 세포
RS53841B1 (sr)	2007-09-28	2015-06-30	Anthrogenesis Corporation	Supresija tumora korišćenjem humanog placentalnog perfuzata i intermedijernih ćelija ubica poreklom iz humane placente
DK2217329T3 (da) *	2007-11-07	2018-04-23	Anthrogenesis Corp	Anvendelse af navlestrengsblod i behandlingen af komplikationer i forbindelse med præterm fødsel
KR20180108887A (ko) *	2008-08-20	2018-10-04	안트로제네시스 코포레이션	단리된 태반 세포를 사용한 뇌졸중 치료
DK2330889T3 (da) *	2008-08-20	2017-01-30	Anthrogenesis Corp	Forbedret cellesammensætning og fremgangsmåde til fremstilling af samme
MX2011001992A (es) *	2008-08-22	2011-03-29	Anthrogenesis Corp	Metodos y composiciones para el tratamiento de defectos oseos con poblaciones de celulas placentarias.
CA2743566C (en) *	2008-11-19	2021-11-09	Anthrogenesis Corporation	Amnion derived adherent cells
NZ602569A (en) *	2008-11-21	2014-03-28	Anthrogenesis Corp	Treatment of diseases, disorders or conditions of the lung using placental cells
AR077369A1 (es)	2009-07-02	2011-08-24	Anthrogenesis Corp	Metodopara producir eritrocitos sin celulas alimentadoras
WO2011094181A1 (en) *	2010-01-26	2011-08-04	Anthrogenesis Corporation	Treatment of bone-related cancers using placental stem cells
SI2556145T1 (sl)	2010-04-07	2017-01-31	Anthrogenesis Corporation	Angiogeneza z uporabo placentnih matičnih celic
AU2011237743A1 (en)	2010-04-08	2012-11-01	Anthrogenesis Corporation	Treatment of sarcoidosis using placental stem cells
CN107828727A (zh)	2010-07-13	2018-03-23	人类起源公司	产生自然杀伤细胞的方法、由此获得的细胞群体及其用途
PT2621515T (pt)	2010-09-28	2017-07-12	Aegerion Pharmaceuticals Inc	Polipéptido quimérico de leptina de foca-ser humano com solubilidade aumentada
AR093183A1 (es)	2010-12-31	2015-05-27	Anthrogenesis Corp	Aumento de la potencia de celulas madre de placenta usando moleculas de arn moduladoras
EP3443968A1 (en)	2011-06-01	2019-02-20	Celularity, Inc.	Treatment of pain using placental stem cells
WO2013055476A1 (en)	2011-09-09	2013-04-18	Anthrogenesis Corporation	Treatment of amyotrophic lateral sclerosis using placental stem cells
AU2014215458A1 (en)	2013-02-05	2015-08-13	Anthrogenesis Corporation	Natural killer cells from placenta
MA42613A (fr)	2015-08-13	2018-06-20	Amgen Inc	Filtration en profondeur chargée de protéines de liaison à un antigène

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4165370A (en)	1976-05-21	1979-08-21	Coval M L	Injectable gamma globulin
JPS5534001A (en) *	1978-08-28	1980-03-10	Noda Sangyo Kagaku Kenkyusho	Stabilization of sarcosine oxidase
US4783441A (en)	1979-04-30	1988-11-08	Hoechst Aktiengesellschaft	Aqueous protein solutions stable to denaturation
DE3176491D1 (en)	1980-03-05	1987-11-26	Miles Lab	Pasteurized therapeutically active protein compositions
JPS5874617A (ja)	1981-10-28	1983-05-06	Green Cross Corp:The	人由来血液凝固第７因子含有水溶液の加熱処理方法
JPS58134991A (ja) *	1981-12-28	1983-08-11	Takeda Chem Ind Ltd	セラチオペプチタ−ゼの安定化法
JPS59134730A (ja)	1983-01-20	1984-08-02	Green Cross Corp:The	血液凝固第８因子の加熱処理法
FI86885C (fi)	1984-04-20	1992-10-26	Genentech Inc	Foerfarande foer framstaellning av human rekombinantfaktor viii och nukleinsyrasekvenser och vektorer anvaend daertill
SE8501050D0 (sv)	1985-03-05	1985-03-05	Kabivitrum Ab	Biologically active fragments of human antihemophilic factor and method for preparation thereof
CA1292686C (en)	1986-10-27	1991-12-03	Ze'ev Shaked	Pharmaceutical compositions of recombinant interleukin-2 and formulation process
NZ226170A (en)	1987-09-18	1990-07-26	Ethicon Inc	Stable freeze-dried pharmaceutical composition containing epidermal growth factor
CA1329760C (en) *	1987-10-29	1994-05-24	Ted C. K. Lee	Plasma and recombinant protein formulations in high ionic strength media
US4877608A (en) *	1987-11-09	1989-10-31	Rorer Pharmaceutical Corporation	Pharmaceutical plasma protein formulations in low ionic strength media
US5096885A (en)	1988-04-15	1992-03-17	Genentech, Inc.	Human growth hormone formulation
EP0381345B1 (en)	1989-01-30	1994-07-13	Corint, Ltd.	Aqueous liquid desmopressin-CMC pharmaceutical composition
JPH02268681A (ja) *	1989-04-07	1990-11-02	Green Cross Corp:The	ウロキナーゼ前駆体の安定化方法及び乾燥製剤
EP0420964A4 (en) *	1989-04-11	1991-09-25	Immunobiology Research Institute, Inc.	Lyophilized peptide formulations
EP1241258A3 (en)	1989-10-16	2003-12-10	Amgen Inc.	Stem cell factor
RU2212411C2 (ru)	1989-10-16	2003-09-20	Эмджен Инк.	Полипептид, обладающий гемопоэтической биологической активностью фактора стволовых клеток (варианты), днк (варианты), экспрессирующий вектор (варианты), фармацевтическая композиция для гемопоэтической терапии, способ получения полипептида и способ его использования (варианты)
SE465222C5 (sv)	1989-12-15	1998-02-10	Pharmacia & Upjohn Ab	Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
DE4001451A1 (de)	1990-01-19	1991-08-01	Octapharma Ag	Stabile injizierbare loesungen von faktor viii und faktor ix
EP0536317A1 (en)	1990-06-25	1993-04-14	Immunex Corporation	Mast cell growth factor
DE69233704T2 (de) *	1991-12-20	2008-05-21	Novo Nordisk A/S	Stabilisierte pharmazeutische Formulierung, umfassend Wachstumshormon und Histidin
US5192743A (en)	1992-01-16	1993-03-09	Genentech, Inc.	Reconstitutable lyophilized protein formulation
CZ290342B6 (cs) *	1992-10-02	2002-07-17	Genetics Institute Inc.	Kompozice stabilní při skladování, obsahující koagulační faktor VIII a neiontovou povrchově aktivní látku a způsob její výroby

1993
- 1993-12-22 US US08/172,507 patent/US6288030B1/en not_active Expired - Fee Related
1994
- 1994-12-20 IL IL11208894A patent/IL112088A/en not_active IP Right Cessation
- 1994-12-21 ES ES95906058T patent/ES2123951T3/es not_active Expired - Lifetime
- 1994-12-21 WO PCT/US1994/014739 patent/WO1995017206A1/en not_active Ceased
- 1994-12-21 CA CA002182970A patent/CA2182970C/en not_active Expired - Fee Related
- 1994-12-21 DK DK95906058T patent/DK0732935T3/da active
- 1994-12-21 EP EP95906058A patent/EP0732935B1/en not_active Expired - Lifetime
- 1994-12-21 CN CN94195012A patent/CN1105575C/zh not_active Expired - Fee Related
- 1994-12-21 AU AU14422/95A patent/AU696860B2/en not_active Ceased
- 1994-12-21 AT AT95906058T patent/ATE173402T1/de not_active IP Right Cessation
- 1994-12-21 DE DE69414723T patent/DE69414723T2/de not_active Expired - Lifetime
- 1994-12-21 ZA ZA9410189A patent/ZA9410189B/xx unknown
- 1994-12-21 NZ NZ278252A patent/NZ278252A/en not_active IP Right Cessation
1998
- 1998-06-29 US US09/106,891 patent/US5965522A/en not_active Expired - Fee Related
1999
- 1999-04-15 US US09/292,222 patent/US6020469A/en not_active Expired - Fee Related
2000
- 2000-12-20 US US09/748,592 patent/US20020013258A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CN1142771A (zh)	1997-02-12
IL112088A (en)	2001-04-30
AU1442295A (en)	1995-07-10
EP0732935A1 (en)	1996-09-25
US6020469A (en)	2000-02-01
IL112088A0 (en)	1995-03-15
DE69414723T2 (de)	1999-07-22
DE69414723D1 (de)	1998-12-24
NZ278252A (en)	1998-04-27
EP0732935B1 (en)	1998-11-18
CN1105575C (zh)	2003-04-16
ZA9410189B (en)	1995-08-25
US5965522A (en)	1999-10-12
CA2182970C (en)	2000-11-28
US20020013258A1 (en)	2002-01-31
ATE173402T1 (de)	1998-12-15
US6288030B1 (en)	2001-09-11
HK1008815A1 (en)	1999-05-21
ES2123951T3 (es)	1999-01-16
AU696860B2 (en)	1998-09-17
WO1995017206A1 (en)	1995-06-29
CA2182970A1 (en)	1995-06-29

Publication	Publication Date	Title
ATE173402T1 (de)	1998-12-15	Lyophilisierte stammzellenfaktor formulierungen
IL113578A (en)	1999-10-28	Stable freeze-dried formulation comprising a protein
ATE270557T1 (de)	2004-07-15	Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen
DE3778287D1 (de)	1992-05-21	Peptidische zusammensetzung.
GR3006172T3 (da)	1993-06-21
FI952797A0 (fi)	1995-06-07	D-vitamiinianalogin uusi kiteinen muoto
AU5327386A (en)	1986-08-21	Peptide derivatives, analogous to pepstatin, which inhibit renin and acid proteases.
BG99177A (bg)	1995-07-28	Нови 7 бета-заместени-4-аза-5 алфа-холестанони като инхибитори на 5 алфа-редуктаза
DK0495918T3 (da)	1996-02-19	Aminosyre-beta-lyaseenzyminhibitorer som deodoranter
DK0601154T3 (da)	1998-02-23	BPC-peptider, deres fremstilling og anvendelse
FI955130A7 (fi)	1995-12-27	L-aminohappo-oksidaasi
EP0727996A4 (en)	1996-11-06	Fenbendazole formulations
ES2058479T3 (es)	1994-11-01	Compuestos peptidicos.
ATE41773T1 (de)	1989-04-15	4,5-dihydro-4-oxo-2((2-transphenylcyclopropyl)amino>-3-furancarbonsaeuren und derivate davon.
FI945252A0 (fi)	1994-11-08	Stabiileja lyofilisoituja tiotepakoostumuksia
BG100248A (bg)	1996-07-31	Инхибитори на скваленсинтетаза
DE69521315D1 (de)	2001-07-19	Hirudin enthaltende pharmazeutische zusammensetzungen
DE3152363T1 (da)	1982-10-07
DK177791A (da)	1992-05-11	Tensidfrie, faste enzympraeparater omfattende protease som virksomt enzym
ATE204286T1 (de)	2001-09-15	Modifizierte alpha-d-glcp-(1,2)-alpha-d-glcp-(1, 3)-alpha-d-glcp-analoge
NO164100C (no)	1990-08-29	Analogifremgangsmaate for fremstilling av terapeutisk aktive 5-klor-s-triazolo-(4,3-a)-pyridin-7-carboxyl-syrer.
AU639751B2 (en)	1993-08-05	Temporary minimal protection synthesis of lh-rh analogs
IT8423664A0 (it)	1984-11-20	Realizzate in applicazione al detto metodo per la produzione metodo. industriale di calzature, in particolare ciabatte, di notevole leggerezza ed utilizzabili sia da casa che all'aperto, e calzature
FI852990L (fi)	1986-02-04	Saosom antiarytmiska aemnen anvaendbara 2,5-pyrrolidindionderivat.
IT8420913A0 (it)	1984-05-14	Leggerezza ed utilizzabili sia da metodo per la produzione casa che all'aperto, e calzature industriale di calzature, in realizzate in applicazione al detto particolare ciabatte, di notevole metodo.